"Carbolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of pyrido-indole compounds. Included are any points of fusion of pyridine with the five-membered ring of indole and any derivatives of these compounds. These are similar to CARBAZOLES which are benzo-indoles.
| Descriptor ID |
D002243
|
| MeSH Number(s) |
D03.383.725.150 D03.633.100.473.155 D03.633.300.154
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Carbolines".
Below are MeSH descriptors whose meaning is more specific than "Carbolines".
This graph shows the total number of publications written about "Carbolines" by people in this website by year, and whether "Carbolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carbolines" by people in Profiles.
-
Functional connectivity abnormalities in clinical variants of progressive supranuclear palsy. Neuroimage Clin. 2025; 45:103727.
-
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer. Expert Rev Anticancer Ther. 2025 Jan; 25(1):27-40.
-
Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer. Thyroid. 2024 Sep; 34(9):1177-1180.
-
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Med. 2024 Jul; 13(14):e70028.
-
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol. 2024 06 13; 31(6):3342-3349.
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases. Lung Cancer. 2024 02; 188:107448.
-
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study. Invest New Drugs. 2023 10; 41(5):677-687.
-
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer. 2022 Sep; 172:340-348.
-
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 07 01; 28(13):2762-2770.
-
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. Cancer Chemother Pharmacol. 2021 01; 87(1):113-124.